The Infectious Disease Research Institute (IDRI), a Seattle-based not-for-profit organization, has partnered with a full-service, Research Triangle, NC-based contract research organization called FHI Clinical to support full-service research capabilities for an immunotherapy clinical trial to combat moderate to severe cases of COVID-19.
TrialSite News recently introduced Celularity, a clinical-stage therapeutic company to launch a clinical trial to investigate the use of Celularity’s NK cell therapy, currently under study for the treatment of various hematologic cancers and solid tumors, as a potential treatment option against COVID-19.
Can Cell Therapy Help Address Crisis?
The hope is that the Celularity’s cell therapy (IMPACT™ Platform) can be a way of offering patients the immune cells that might make a difference in combating the deadly pathogen. Novel therapies may make a difference, reports Ted Fitzgerald, FHI Clinical president and CEO. Fitzgerald noted, “When an outbreak like coronavirus occurs, new therapies and vaccines are vital and require rapid start-up of clinical trials.”
FHI Clinical Outbreak Guide
FHI offers information on the importance of building...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).